Bone Biologics Corporation
2 Burlington Woods Drive, Suite 100
Burlington, MA 01803
February 29, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jane Park
| Re: | Bone Biologics Corporation Registration Statement on Form S-1 File No. 333-276771 |
Ladies and Gentlemen:
On February 28, 2023, Bone Biologics Corporation (the “Company”) requested acceleration of the effective date of the above-referenced Registration Statement so that it would become effective at 5:15 p.m. Eastern Time on February 29, 2024 or as soon thereafter as practicable. The Company hereby withdraws that request and respectfully requests, in accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, the effectiveness of the above-referenced Registration Statement on March 1, 2024 at 1:00 p.m. Eastern Time or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Alexander R. McClean of Harter Secrest & Emery at (585) 231-1248.
| Very truly yours, | ||
| Bone Biologics Corporation | ||
| By: | /s/ Jeffrey Frelick | |
| Jeffrey Frelick | ||
| President and Chief Executive Officer | ||